Core Viewpoint - The company, Panlong Pharmaceutical, has received approval from the National Medical Products Administration for clinical trials of its drug, Flurbiprofen patch, targeting pain relief and anti-inflammatory effects for various conditions [1] Group 1: Clinical Trial Approval - The National Medical Products Administration has issued a Clinical Trial Approval Notice for the Flurbiprofen patch [1] - The approved indications for the clinical trial include osteoarthritis, periarthritis of the shoulder, tendinitis, tenosynovitis, peritendinitis, lateral epicondylitis (such as tennis elbow), muscle pain, and swelling and pain after injury [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of the drug Fluorobufen patch, which is designed for pain relief and anti-inflammatory treatment in various conditions [1] Group 1: Product Details - The Fluorobufen patch was developed by Taisho Pharmaceutical Co., Ltd. and was first approved for sale in Japan on July 23, 1998 [1] - Indications for the product include osteoarthritis, periarthritis of the shoulder, tendinitis, tenosynovitis, lateral epicondylitis (such as tennis elbow), muscle pain, and swelling and pain after injury [1] - The product is classified as a Class 3 chemical drug and has not yet been launched in the domestic market [1] Group 2: Product Features - The patch features a controlled-release membrane design, which allows for a large drug load, low irritation, and a reduced likelihood of causing skin allergies [1] - It is particularly suitable for chronic pain conditions and scenarios where there is a higher demand for the patch's elasticity and adhesion [1]

Industry Overview - The gynecological medication industry encompasses drugs for the prevention, diagnosis, and treatment of gynecological diseases, including traditional hormone therapies, antibiotics, analgesics, and immunomodulators [1][3] - The market for gynecological medications in China has shown rapid growth, with the market size increasing from 27.735 billion yuan in 2012 to an estimated 56.137 billion yuan in 2024, reflecting a compound annual growth rate (CAGR) of 6.05% [1][9] - By 2025, the market size is projected to reach approximately 59.53 billion yuan, driven by increasing awareness of women's health and societal emphasis on female health [1][9] Market Dynamics - The prevalence of gynecological diseases among adult women in China is high, with an estimated incidence rate between 40% and 70%, including conditions such as tumors, cysts, reproductive-related diseases, and gynecological inflammation [6] - The rise in gynecological disease rates and the growing health consciousness among women are contributing to the steady expansion of the gynecological medication market [6] Industry Chain - The gynecological medication industry chain consists of upstream raw materials, intermediates, and pharmaceutical equipment; midstream production; and downstream distribution through pharmacies, hospitals, and e-commerce platforms [6][7] Key Companies - Notable companies in the gynecological medication sector include Qianjin Pharmaceutical, Tongrentang, Kangyuan Pharmaceutical, Jiuzhitang, Yunnan Baiyao, and others, which are focusing on R&D and product differentiation [10][11] Development Trends - Future product development in gynecological medications is expected to shift towards precision and individualized treatment, utilizing diagnostic technologies to enhance treatment efficacy and reduce side effects [12] - Innovations in drug formulations and delivery methods will improve patient compliance and experience, with a focus on long-acting, user-friendly options [13] - The role of gynecological medication companies is evolving from mere drug suppliers to providers of comprehensive health management solutions for women throughout their life stages [14]

Industry Overview - The Chinese traditional medicine sector is experiencing performance pressure due to weak sales in pharmacies and hospitals since 2025, leading to a divergence in the performance of listed companies [3] - OTC leading enterprises show strong performance resilience, while the industry is undergoing a painful transition in its development model amid healthcare reform [3] - Future success will depend on diversified channels, strong brand power, and high clinical value, with long-term policies guiding the industry towards high-quality and standardized development [3] - The market for traditional Chinese medicine is rapidly growing, with new products driving growth momentum [3] - Continuous favorable measures from the supply, payment, and demand sides are promoting the prosperity and development of the traditional Chinese medicine industry [3] Company Overview - Panlong Pharmaceutical, a leading enterprise in the field of traditional Chinese medicine for rheumatology and orthopedics, has 25 production lines certified by the new national GMP, producing tablets and capsules [3] - The company has developed a strong product lineup, including the nationally exclusive patented product "Panlong Seven Tablets," covering 12 major functional categories and over 100 specifications [3] - The company is actively expanding its online sales channels for health products across six platforms, including JD.com, Taobao, Weimeng, WeChat Mini Programs, Video Number, and Douyin [4] - Panlong Pharmaceutical is expected to benefit from policy dividends, the accelerating trend of population aging, and consumption upgrades [5]

Summary of Panlong Pharmaceutical Conference Call Company Overview - **Company Name**: Panlong Pharmaceutical - **Established**: 1997, listed on Shenzhen Stock Exchange in 2017 - **Core Product**: Panlong Seven Tablets, a patented Class A medical insurance product - **Production Capacity**: 25 production lines certified by the new national GMP, with supporting inspection and research facilities [3][4] Industry and Market Position - **Market Coverage**: Active in 30 provinces, with over 650 commercial partners and access to more than 5,000 medical institutions and 50,000 grassroots medical units [2][5] - **Future Expansion**: Plans to expand into southern markets [2][5] - **Growth Drivers**: Significant growth in traditional Chinese medicine (TCM) sales, particularly in TCM slices, with over 4,440 varieties and 25 fine powder approvals [8][5] Financial Projections - **2026 Revenue Target**: Estimated at 1.8 billion yuan, focusing on TCM slices, innovative drugs, and hospital preparations [3][30] - **Panlong Seven Tablets Sales Forecast**: Expected to reach 650 million yuan in 2026, with a potential 30% increase if included in the essential drug list [2][20][29] Product Development and Innovation - **New Product Launches**: Plans to introduce 3-4 best-selling new products in the next 3-5 years, including Panlong Seven Gel Patch and Loxoprofen Sodium [3][15][23] - **Current Product Line**: Includes TCM slices, TCM formula granules, and innovative drugs, with a focus on classic formulations and chemical preparations [3][15] Competitive Advantages - **Unique Selling Proposition**: Panlong Seven Tablets consist of 29 herbal ingredients, including 17 rare medicinal materials, with proven efficacy and safety, recommended by clinical guidelines [18][19] - **Supply Chain Stability**: Raw material costs are stable due to self-sufficient production bases and partnerships for cultivation [12][19] Marketing and Sales Strategy - **Sales Channels**: Traditional hospital sales are increasing, with a shift from 80:20 to 70:30 in favor of hospital sales [26][28] - **Online Sales**: Managed by subsidiary Panlong Yunkuang Technology, with plans for online promotions through partnerships with media and internet companies [16][26] Challenges and Risks - **Market Competition**: The TCM formula granules market is competitive, but the company is optimistic about its unique production capabilities in Shaanxi province [13][14] - **Regulatory Changes**: Potential changes in the essential drug directory could impact market dynamics and sales strategies [20][22] Future Outlook - **Long-term Strategy**: Focus on expanding market share in TCM slices and innovative drugs, while also developing the health product segment [17][30] - **Production Capacity Assurance**: Prepared for increased demand with production line arrangements to ensure capacity [29] Additional Notes - **Collaboration Projects**: Ongoing collaboration with Qianchuan Pharmaceutical for establishing a Chinese herbal medicine base, with updates expected in future reports [11] - **Profit Margins**: Specific gross margin data for TCM slices not disclosed, but expected to be competitive with industry standards [10]

Meeting Details - The first temporary shareholders' meeting of 2026 was held on January 16, 2026, at 14:00 [1] - The meeting combined on-site voting and online voting, with specific time slots for each [2] - The meeting was convened by the board of directors and presided over by Chairman Mr. Xie Xiaolin [3][4] Attendance - A total of 245 shareholders attended the meeting, representing 43,820,617 shares, which is 41.3763% of the total voting shares [5] - Among them, 7 shareholders attended in person, representing 39,536,232 shares (37.3309%), while 238 participated via online voting, representing 4,284,385 shares (4.0454%) [5] - Small and medium shareholders accounted for 5,359,385 shares (5.0604%) of the total voting shares [6] Resolutions Passed - The proposal to conclude fundraising projects and permanently supplement working capital with surplus funds was approved, with 43,776,623 shares (99.8996%) in favor [8] - The proposal to elect additional members to the fifth board of directors was also approved, with 43,774,186 shares (99.8940%) in favor [11] Legal Opinion - The legal opinion provided by Beijing Ruqiang Law Firm confirmed that the meeting's procedures, attendance qualifications, and voting processes complied with relevant laws and regulations, deeming the resolutions legal and valid [14]

陕西盘龙药业集团股份有限公司 2026年1月16日 关于完成第五届董事会董事补选的公告 特此公告。 陕西盘龙药业集团股份有限公司董事会 证券代码：002864 证券简称：盘龙药业 公告编号：2026-002 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 陕西盘龙药业集团股份有限公司（以下简称"公司"）于2026年1月16日召 开2026年第一次临时股东会，审议通过了《关于补选第五届董事会董事的议案》， 同意选举孟重先生为公司第五届董事会非独立董事。任期自股东会审议通过之日 起至本届董事会任期届满之日止。公司第五届董事会中兼任公司高级管理人员以 及由职工代表担任的董事人数总计不超过公司董事总数的二分之一。孟重先生简 历详见公司于2025年12月30日在巨潮资讯网(http://www.cninfo.com.cn)披露的 《关于调整公司董事及高级管理人员的公告》。 1 ...

北京瑞强律师事务所 二零二六年一月 0 地 址：北京市东城区银河 SOHO B 座 1509-1510 室 电 话：010-58116099 传 真：010-58116099 Email：Recher@bjrecher.com 关于陕西盘龙药业集团股份有限公司 2026 年第一次临时股东会 之 法律意见书 北京瑞强律师事务所 关于陕西盘龙药业集团股份有限公司 2026 年第一次临时股东会 之 法律意见书 北京瑞强律师事务所（以下简称"本所"）接受陕西盘龙药业集团股份有限公 司（以下简称"公司"）的委托，指派本所陈晓昀律师、王志恒律师出席公司于 2026 年 1 月 16 日下午 14:00 在陕西省西安市灞桥区现代纺织产业园灞柳二路 2801 号陕西盘龙医药股份有限公司二楼会议室召开的 2026 年第一次临时股东会 （以下简称"本次股东会"）。现依据《中华人民共和国公司法》（以下简称"《公 司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《深圳证券交 易所上市公司股东会网络投票实施细则》（以下简称"《网络投票细则》"）《上 市公司股东会规则》（以下简称"《股东会规则》"）等法律、行政法规、其他规 ...

证券代码：002864 证券简称：盘龙药业 公告编号：2026-001 陕西盘龙药业集团股份有限公司 关于 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决提案的情形。 2.本次股东会不涉及变更以往股东会已通过的决议的情形。 一、会议召开和出席情况： （一）会议召开时间： 1.现场会议召开日期：2026 年 1 月 16 日（星期五）下午 14:00。 2.网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为 2026 年 1 月 16 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00；通过深圳 证券交易所互联网投票系统投票的具体时间为 2026 年 1 月 16 日 9:15—15:00 期间的任意时间。 （二）现场会议召开地点：西安市灞桥区现代纺织产业园灞柳二路2801号陕 西盘龙医药股份有限公司二楼会议室。 （三）会议召开和表决方式：采用现场表决与网络投票相结合的方式。 （四）召集人：董事会。 （五）会议主持人：董事长谢晓林先生。 （六）本 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.59% on January 16, with *ST Changyao leading the drop [1] - The Shanghai Composite Index closed at 4101.91, down 0.26%, while the Shenzhen Component Index closed at 14281.08, down 0.18% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Tianmu Pharmaceutical (600671) with a closing price of 18.41, up 4.07% [1] - Zhongsheng Pharmaceutical (002317) at 22.10, up 3.32% [1] - Weikang Pharmaceutical (300878) at 32.84, up 2.34% [1] - Conversely, *ST Changyao (300391) saw a significant drop of 20.59%, closing at 0.54 [2] Trading Volume and Value - The trading volume and value for selected stocks were as follows: - Zhongsheng Pharmaceutical had a trading volume of 862,100 shares and a transaction value of 1.854 billion [1] - Weikang Pharmaceutical recorded a trading volume of 161,200 shares with a transaction value of 207 million [1] - The overall net outflow of funds in the Chinese medicine sector was 299 million, while retail investors saw a net inflow of 62.16 million [2] Fund Flow Analysis - Major fund flows indicated: - Zhongsheng Pharmaceutical had a net inflow of 1.57 billion from major funds, but a net outflow of 22.56 million from speculative funds [3] - Yunnan Baiyao (000538) saw a net inflow of 61.66 million from major funds, with a net outflow of 24.37 million from speculative funds [3] - The overall sentiment reflected a mixed response from different investor categories, with major funds showing a preference for certain stocks while speculative funds exhibited outflows [3]